Search
Cellectar Biosciences Inc
CLRBAdd to Watchlist
2.090USD
-0.140-6.28%
Close 09-22 16:00（ET）
16.70MMarket Cap
LossP/E TTM
Cellectar Biosciences Inc (CLRB) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Cellectar Biosciences Inc in the past month.
Buy
1 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
11.500USD+415.70%
CLRB Analyst Recommendation Trends
In the current month, CLRB has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CLRB average Analyst price target in the last month is 11.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
0
1
1
1
3
3
2
2
2
1
1
1
0
0
0
0
0
1
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
3
3
2
3
4
4
CLRB Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, CLRB EPS is projected to reach -0.557 in FY2026Q3, following reported EPS of -0.567 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-2.29
-1.89
-0.48
-0.56
-0.53
Actual
-1.29
-1.33
-0.57
--
--
Surprise
+43.80%
+29.26%
-17.23%
--
--
FAQs
What is Cellectar Biosciences Inc's price target?
Analysts forecast that Cellectar Biosciences Inc's price target is USD 11.50, with the highest forecast at USD 15.00 and the lowest forecast at USD 10.00.
How have Cellectar Biosciences IncCLRB's recent earnings per share performed?
The market expectation was USD -0.57, while Cellectar Biosciences IncCLRB's earnings per share (EPS) for the previous quarter was USD -1.33. EPS for the next quarter is expected at USD -0.58.
What is the analyst rating for Cellectar Biosciences Inc?
Based on the ratings of Cellectar Biosciences Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.